Jun. 23 at 1:42 PM
GLMD could be the most asymmetric biotech setup of the year. Sitting near
$1 with
$20M+ cash, no toxic dilution, and a definitive GLP-1 agreement due within weeks. Book value near
$12, ran to
$24 last cycle, and now floating under radar. When catalysts hit, there may not be time to chase. Get in before the crowd does. #biotech #GLP1 #smallcaps
$GLMD $TTOO $HOTH $SNTI